Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.
about
Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid LeukemiaCarfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition.High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia.Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56.Hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival.Should we also evaluate SET together with CIP2A for the treatment with second-generation tyrosine kinase inhibitors in chronic myeloid leukemia?
P2860
Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Second generation tyrosine kin ...... ic myeloid leukaemia patients.
@en
type
label
Second generation tyrosine kin ...... ic myeloid leukaemia patients.
@en
prefLabel
Second generation tyrosine kin ...... ic myeloid leukaemia patients.
@en
P2093
P2860
P356
P1433
P1476
Second generation tyrosine kin ...... nic myeloid leukaemia patients
@en
P2093
A K Holcroft
E McDonald
R J Harris
P2860
P2888
P304
P356
10.1038/LEU.2015.71
P577
2015-03-13T00:00:00Z
P6179
1027240081